Objective: To analyze the association between smoking and oncological outcome after radical prostatectomy in patients with prostate cancer. Methods: This study included men who underwent radical prostatectomy between 2003 and 2013. The association of clinicopathological factors with smoking status and the prognostic significance of clinicopathological factors and smoking status on biochemical recurrence (BCR) were evaluated. Results: Of the 1165 included patients, 226 (19.4%) were current smokers and 939 (80.6%) were nonsmokers. The median observation period was 39 months (interquartile range, 15-75 months). Current smokers were younger than nonsmokers and had higher PSA levels, higher biopsy and pathological Gleason scores, and more frequent lymph-node involvement than nonsmokers. Pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin, lymph-node involvement, and current smoking (hazard ratio [95% confidence interval]; 1.31 [1.00-1.72], P = 0.046) were identified as significant risk factors of BCR on univariate analysis. However, smoking status was not an independent predictive marker on multivariate analysis. Conclusions: Current smokers had adverse clinicopathological characteristics including high PSA level, high Gleason score, and lymph node involvement, suggesting that smoking promoted the progression of prostate cancer.
Introduction
Prostate cancer is the second most prevalent male cancer worldwide (1) . Older age and genetic factors such as race and family history are recognized as non-modifiable risk factors for prostate carcinogenesis (2, 3) , in addition to environmental risks such as diet (calcium, meat and fat), lifestyle, hormonal status including testosterone level and inflammation (4) . Smoking has been proposed as an environmental factor that increases the risk of prostate (5, 6) , and other cancers including cancer of the lung, bladder and kidney, although a recent meta-analysis found an inconsistent association between cigarette smoking and prostate cancer incidence (7) .
In addition to its carcinogenic effects, smoking has been seen as promoting progression and recurrence of prostate, lung, bladder, and other cancers because of its mutagenic effects. Most prospective studies have found an association of current smoking with a fatal outcome of prostate cancer (8) . For localized prostate cancer, radical prostatectomy (RP) has been a gold-standard therapeutic option. However, biochemical recurrence (BCR) has been shown to occur within 10 years in 17-53% of men treated with RP for prostate cancer (9, 10) . Smoking has been associated with worse prognosis in addition to high prostate-specific antigen (PSA) level, high Gleason score and advanced disease in men in Western countries (11) (12) (13) , but one study failed to show an association between smoking and outcome after RP in Asian men (14) . Thus, the significance and robustness of the effects of smoking on the progression and recurrence of prostate cancer remain unclear, especially in Asian populations.
It is necessary to identify intervention targets other than clinicopathological factors that can act to prevent the progression and recurrence of prostate cancer. Smoking is a potential target along with diet, lifestyle, and environmental factors. We aimed to investigate the association of smoking and oncological outcomes including clinicopathological characteristics and BCR in Japanese men after RP.
Patients and methods
We enrolled 1165 men whose information on smoking status was available among patients who received RP as primary treatment for prostate cancer at Harasanshin Hospital and Kyushu University Hospital (Fukuoka, Japan) between 2003 and 2013. This study was approved by each institutional review board . Patients with neo-adjuvant/adjuvant hormonal therapy (n = 71), with no malignancy (n = 14), and missing follow-up data (n = 50) were excluded from the analysis. None of the patients had been given neo-adjuvant/ adjuvant radiotherapy or chemotherapy. In addition to smoking status, patient data included age, PSA at diagnosis, clinical and pathological T-stages, biopsy and pathological Gleason score, resection margin status, extracapsular extension, seminal vesicle invasion and lymph node involvement.
RP was performed by open retropubic, laparoscopic or robotassisted procedures by a number of different surgeons. Surgical procedures and nerve-sparing were chosen dependent on the institution and consideration of BCR risk. Bilateral lymph-node dissection in the regions along the external and internal iliac vessels and within the obturator fossa was performed depending to the operation procedures; the risk of lymph-node involvement was determined by preoperative assessment. BCR was defined as absence of PSA values <0.2 ng/ml or presence of two consecutive postoperative PSA values >0.2 ng/ml. The date of BCR was defined as the date of the first of these PSA measurements. If postoperative PSA level did not fall below 0.2 ng/ml, the day of surgery was defined as the date of BCR.
Patients were divided into two groups by smoking status at the time of RP. Nonsmokers included those who had never smoked (n = 542) plus former smokers (n = 397). BCR-free survival was determined by the Kaplan-Meier method and the log-rank statistic was used to compare survival durations across risk groups. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. Correlations between categorical and continuous parameters were examined chi-square tests and Mann-Whitney U tests, respectively. All P values were two-sided and P < 0.05 was considered significant. All statistical analyses were performed using EZR (15) .
Results
We enrolled a total of 1165 Japanese men who underwent RP for prostate cancer. The clinicopathological characteristics of the patients are shown in Table 1 . When the RP was performed, 226 men (19.4%) were smokers and 939 (80.6%) were nonsmokers. As shown Table 1 , current smokers were younger (P < 0.001), had higher PSA levels (P = 0.012), higher Gleason scores at biopsy (P = 0.019) and RP (P = 0.030), and more frequent lymph-node involvement (P < 0.001) than nonsmokers. The surgical margin status, presence of extracapsular extension and seminal vesicle invasion were not significantly different. There were no differences in clinicopathological parameters between former smokers and men who had never smoked, except for positive surgical margins, which were more frequent in those who had never smoked (data not shown).
The impact of clinicopathological parameters on BCR are shown in Table 2 . Univariate analysis identified PSA level at diagnosis, clinical T-stage, biopsy and pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin and lymph-node involvement as significant risks of BCR. Univariate analysis also found that smoking status was also associated with BCR (hazard ratio [95% confidence interval]; 1.31 [1.00-1.72], P = 0.048) although not associated with overall survival (data not shown).
Over a median observation period of 39 months (interquartile range, 15-75 months), 70 of the 226 smokers (31%) and 216 of 939 nonsmokers (23%) experienced a BCR. Kaplan-Meier analysis ( Fig. 1) found that the BCR-free survival rate was significantly worse rate in the smoking than in the nonsmoking group (log-rank, P = 0.046). The 5-year BCR-free survival rate was 67.1% in smokers and 73.0% in nonsmokers. Among nonsmokers, BCR-free survival was similar in former smokers and those who had never smoked (data not shown).
Multivariate analysis identified PSA level at diagnosis, clinical T-stage, and biopsy Gleason score, but not smoking status as significant preoperative risks of BCR (Supplementary Table 1 ). Multivariate analysis also identified pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margins, lymphnode involvement, but not PSA level at diagnosis or smoking status, as significant postoperative risks of BCR (Supplementary Table 2 ).
Comment
Several parameters, including PSA at diagnosis, PSA density, clinical and pathological stages, biopsy and pathological Gleason scores, resection margin status, extracapsular extension, seminal vesicle invasion, perineural invasion and lymph-node involvement, have been reported as risk factors of BCR (12, 16) . Smoking has also been proposed as a risk of BCR (13) . In this study, multivariate analysis identified pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin and lymph-node involvement were identified as risks of BCR, which is consistent with previous reports. However, smoking was identified as a risk of BCR on univariate, but not multivariate analysis, suggesting that smoking was not an independent risk factor. This study thus failed to show the usefulness of smoking status as a predictive marker of BCR although there may be significant difference when the outcome in only heavy smokers was compared with those in nonsmokers. Although smoking was not predictive of BCR, smoking was significantly associated with adverse pathological features such as higher PSA level, advanced clinical stage, higher Gleason score at biopsy and RP and positive lymph-node status. As a result, risk of BCR was higher among smokers than nonsmokers. Previous reports have consistently shown that smoking was associated with adverse pathological characteristics such as extraprostatic disease extension, higher Gleason score, greater tumor volume in prostatectomy specimens, as well as increased risk of BCR following RP (17) (18) (19) . Smoking has also been associated with adverse outcomes in patients treated with radiotherapy (20) . The above findings suggest that cigarette smoking promotes clinical progression of prostate cancer and increases the likelihood of BCR.
We found almost no difference in oncological outcome after RP between former smokers and men who had never smoked. It was recently reported that not smoking for at least 10 years was associated with reduction in BCR after RP (21) . This may account for the similar outcomes that we saw in those who never smoked and in former smokers. Our results support the hypothesis that long-term smoking cessation and never smoking may both predict a better oncological outcome of prostate cancer. Abstention from tobacco should thus be recommended not only for general health, but also specifically for reducing prostate cancer risks.
Several biological mechanisms of the effect of smoking on the progression of prostate cancer have been proposed (22) . First, smoking raises the circulating levels of androgens, and high levels of circulating testosterone are associated with increased risk of prostate cancer (23, 24) . However, although controversial, low levels of circulating testosterone have been associated with high grades of prostate cancer (25, 26) . Second, inflammation may be a mediator of the adverse effects of smoking on oncological outcome in prostate cancer. In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, smoking was shown to be associated with inflammation of prostate biopsy tissue (27) , which was shown in various preclinical studies to promote prostate cancer progression (28, 29) . Third, enhancement of tumor angiogenesis and immune modulation by smoking might facilitate tumor progression in prostate cancer (22) . Finally, carcinogens in cigarette such as polycyclic aromatic hydrocarbons and nitrosamines may promote the progression to higher grade cancers by inducing mutations in oncogenes or tumor-suppressor genes such as p53 (30) . However, exactly how smoking influences the progression of prostate cancer remains unclear.
This study has some limitations. First, it was retrospective and limited observation period. Second, the RPs were performed by differing procedures and by several surgeons, and several different pathologists evaluated the biopsy and prostatectomy specimens. Third, smoking history was self-reported and subject to recall bias. There was also no information on the years and amount of smoking, and we did not consider second-hand smoking and the smoking status after RP.
In conclusion, current smoking was associated with adverse clinicopathological characteristics including high PSA level, high Gleason score and lymph-node involvement, resulting in increased BCR rate. This is evidence of an association between smoking and adverse oncological outcome after RP among Japanese with prostate cancer. The findings suggest that smoking promoted the progression and recurrence of prostate cancer in this group and may be a potential intervention to prevent the progression of prostate cancer, although not be a predictive marker of BCR after RP.
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